Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | EED | O75530 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31435950 | 0.89 | PTPN11 (0.47) | PTPN11L3MBTL1PDGFRBKDRBRD4 | |
| SCHEMBL31435987 | 0.87 | PTPN11 (0.43) | PTPN11L3MBTL1PDGFRBKDRBRD4 | |
| SCHEMBL11968458 | 0.84 | PTPN11 (0.44) | PTPN11L3MBTL1PDGFRBKDRBRD4 | |
| SCHEMBL31436019 | 0.84 | PTPN11 (0.46) | PTPN11L3MBTL1PDGFRBKDRBRD4 | |
| SCHEMBL31435988 | 0.82 | PTPN11 (0.45) | PTPN11L3MBTL1BRD4PTGS2HTR6 | |
| SCHEMBL15805493 | 0.82 | PTPN11 (0.44) | PTPN11L3MBTL1PDGFRBKDRBRD4 | |
| SCHEMBL1516682 | 0.80 | PTPN11 (0.40) | PTPN11L3MBTL1PDGFRBKDRBRD4 | |
| SCHEMBL1516685 | 0.80 | PTPN11 (0.44) | PTPN11L3MBTL1PDGFRBKDRBRD4 | |
| SCHEMBL30280427 | 0.80 | PTPN11 (0.47) | PTPN11L3MBTL1PDGFRBKDRBRD4 | |
| SCHEMBL12762888 | 0.79 | PTPN11 (0.40) | PTPN11L3MBTL1PDGFRBKDRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2025-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | TYRO3, TH, TYR | PTPN11 65/4885L3MBTL1 3734/4885PDGFRB 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.